The aim was to evaluate two transplant strategies for patients who lack HLA-identical donors, namely HLA-A, HLA-B or -DRb1 mismatched unrelated donor (MM URD) transplants (n ¼ 14) and umbilical cord blood transplants (UCB, n ¼ 27). Diagnosis, disease stage and age were similar in the two groups. Cell dose was lower in the UCB group (Po0.001). Median time to ANC of 40.5 Â 10 9 /l was 30 days in the UCB group and 17 days in the MM URD group (P ¼ 0.002). Engraftment of plt was delayed in the UCB group (P ¼ 0.03). The UCB patients required fewer erythrocyte transfusions (P ¼ 0.001). At 100 days, complete donor chimerism for CD3 was 63 and 44% in the UCB and MM URD groups, respectively. Acute GVHD of grades II-IV were 30% in the UCB group and 21% in the MM URD group. The corresponding figures for chronic GVHD were 9 and 20%, respectively. TRM was 30% in the UCB patients and 50% in the MM URD patients. Three-year survival was 66% in the UCB group and 14% in the MM URD group (P ¼ 0.006). Although the material is small and heterogeneous, engraftment was delayed, leukocyte chimerism was not significantly different and survival was superior using UCB rather than MM URD transplants.
Introduction
The ideal donor for allogeneic hematopoietic SCT (ASCT) is an HLA-identical sibling. However, only around onethird of all patients have access to a suitable sibling donor. With a steady increase in the number of volunteer donors in registries around the world, unrelated donors are used more frequently. 1, 2 With improved genomic tissue typing, results using unrelated donors are very similar to those obtained using HLA-identical siblings. [3] [4] [5] Despite the fact that the volunteer registries now contain more than 12 million unrelated donors, the pool is not large enough to find an HLA-matched donor for all patients. Especially for those with rare HLA alleles, an alternative donor must be sought. There are different strategies for this category of patient. One strategy is to use related HLA-haploidentical donors. 6 We first used an alternative strategy, namely that of using unrelated donors with one major HLA Ag mismatch (MM URD), which are also available for almost all patients. A third possibility is to use umbilical cord blood (UCB). [7] [8] [9] [10] [11] [12] [13] A potential advantage of using UCB is the immediate availability, the lower risk of GVHD and the fact that HLA matching can be less stringent. On the other hand, the use of UCB has been reported to be associated with slower engraftment, increased risk of graft failure and more infections, when compared with other sources of stem cells. A highly important prognostic factor using UCB is the cell dose, with better outcome in those who receive more that 2 Â 10 7 nucleated cells per kg. To overcome this problem, double UCB transplantations or expanded UCB have been used. 14, 15 In this study, we evaluated two strategies, the use of MM URD and the use of unrelated UCB.
Materials and methods

Patients
From January 1992 to November 2006, a total of 14 patients received ASCT from HLA-mismatched unrelated donors and 27 patients received UCB. Patient characteristics such as diagnosis, disease stage, sex and age are given in Table 1 .
Donors and tissue typing
UCBs were searched for through the various cord blood banks worldwide. 11 Units were chosen according to cell dose and degree of HLA matching. We aimed at a cell dose of 42 Â 10 7 /kg. This was not achievable in nine cases, and double UCB grafts were used instead.
14 HLA typing for class I and class II was carried out by allele-level PCR amplification with sequence-specific primers. 5 Of the 27 UCB cases, 1 patient had an HLA-A, -B and -DRb1-matched donor, 1 got a two minor Ag-mismatched graft, 14 had one HLA-Ag mismatch (8 patients, in addition, had minor mismatches) and 12 had two HLA Ag mismatches out of which 6 in addition had minor mismatches ( Table 1) . The MM URD grafts included one HLA-A mismatch in six patients, an HLA-B Ag mismatch in five, and a DRb1 Ag mismatch in three patients. Of the patients who received MM URD, 13 got BM grafts and 1 got a G-CSF-mobilized PBSC graft. T-cell-depleted grafts were given to 11 of these patients. T-cell depletion was carried out using magnetic beads coupled to MoAbs directed against CD2, CD3 and CD8 (Dynal, Oslo, Norway) as previously described. 16 The median nucleated cell dose and CD34 þ cell dose per kg were significantly higher in patients receiving MM URD transplants, when compared with UCB (Table 1) .
Conditioning
Patients receiving UCB and with ALL (n ¼ 8), and one with lymphoma, were treated with CY (120 mg/kg) and fractionated TBI (12 Gy, that is, 3 Gy Â 4) ( Table 1) . Myeloablative BU (16 mg/kg) combined with CY (120 mg/kg) was given to 11 patients. 17 Reduced-intensity conditioning consisting of fludarabine (30 mg/m 2 /day) given for 6 days combined with BU (8 mg/kg) was given to one UCB recipient. In two patients with lymphoma, fludarabine was given for 5 days combined with CY (60 mg/kg) and fractionated TBI (6 Gy, i.e. 3 Gy Â 2). Of the 11 recipients of mismatched unrelated grafts, CY (120 mg/kg) was combined with single-dose (3 patients) or fractionated TBI (14.4 Gy). 18 Three patients with inborn errors of metabolism received BU (16 mg/kg) combined with CY (8 g/m 2 ). Two patients with inborn errors of metabolism were given fludarabine (30 mg/m 2 /day) for 6 days, combined with CY (120 mg/kg). Two patients with Fanconi's anemia were treated with fludarabine combined with treosulfan.
GVHD prophylaxis
A total of 33 patients were given anti-T-cell globulin (ATG) during conditioning (Thymoglobulin, Genzyme, Cambridge, MN, USA), a 6-10 mg/kg total dose in accordance with our protocol using unrelated donors. 19 Five patients were treated with OKT-3 (Orthoclone, Janssen-Cilag, Ta¨by, Sweden). The UCB patients mostly received CYA starting on day À1 before transplantation. 20 CYA was combined with prednisolone in 24 recipients of UCB. In two patients, CYA was combined with mycophenolate mofetil, 21 and in one patient, immunosuppression consisted of sirolimus combined with tacrolimus. 22 Recipients of unrelated mismatched T-celldepleted BM were treated with CYA combined with four doses of MTX. 20 CYA was discontinued 6-24 months after transplant in the absence of GVHD. Acute GVHD of grade I was treated with prednisolone. 20 Chronic GVHD was classified as limited or extensive, and mild, moderate or severe, according to the judgment of the treating physician. 23 
Supportive care
All patients were kept in reversed isolation or treated at home 24 Between 1995 and 2000, G-CSF was given to 11 UCB patients and to 10 recipients of mismatched unrelated grafts, at a dose of 5 mg per day intravenously from day 10 until neutrophil engraftment 40.5 Â 10 9 /l for 2 days. After that, G-CSF prophylaxis was stopped because we found that it resulted in an increased incidence of acute GVHD of grades II-IV. 25 Supportive care has been described in detail previously, especially in BM recipients. 20, 24 Chimerism analysis PCR amplification of variable numbers of tandem repeats was used to evaluate various degrees of donor and recipient chimerism in CD3 þ , CD19 þ and CD33 þ cells enriched from blood samples using immunomagnetic beads (Dynal, Oslo, Norway), as previously described. 26 Complete donor chimerism (DC) was defined as 495% donor cells. In April 2005, we changed to a real-time PCR method based on single nucleotide polymorphism. Table 1 Characteristics of recipients and donors, stem cell content, conditioning and GVHD prophylaxis in recipients of UCB grafts or MM URD transplants The primers and probes were adopted from Alizadeh et al. 27 In short, 11 biallelic genetic systems with 19 markers were used to screen pre-SCT patient and donor DNA samples. An allele was informative when it was positive for patient DNA and negative for donor DNA. Only one marker was used for each patient/donor pair. Detection and quantification was performed on the ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using TaqMan technology. RQ-PCR reactions were performed in a total volume of 25 ml including 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems, containing dNTPs with dUTP, MgCl2, AmpliTaq Gold DNA polymerase, AmpErase UNG, passive reference), 5 ml of DNA sample, 300 nM of each primer and 200 nM probe. The amount of amplifiable DNA in each sample was assessed by parallel amplification of the reference gene GAPDH (glyceraldehyde phosphate dehydrogenase). All samples were run in duplicate, including the pre-SCT DNA samples. Relative quantification of recipient DNA was calculated according to the DDC t method (Applied Biosystems, user bulletin 2) using GAPDH as a reference gene and the pre-SCT patient sample as a calibrator. The formula used was 2 À(DCtUÀDCtC) , where DC t ¼ C t target geneÀC t reference gene. U is the unknown sample and C is the calibrator sample. Chimerism was followed at least monthly until complete DC.
Statistics
Time to survival and relapse-free survival were determined with the life table method using the log-rank (MantelHaenzel) test, taking censored data into account. Incidence of GVHD, TRM and relapse was estimated nonparametrically. Patients were censored at the time of death, relapse or last follow-up. Because relapse and non-relapse mortality are competing events, their incidence rates were estimated using a nonparametric estimator of cumulative incidence curves. Analyses were performed using the cmprsk software package (developed by Gray, June 2001), Splus 6.2 software and Statistica software. The Mann-Whitney U-test was used to compare continuous variables and the Fisher's exact test was used to compare the distribution of categorical variables.
Results
Engraftment and transfusions
In the recipients of UCB, there were two graft failures. There were three in the MM URD group. Median time to ANC of 0.5 Â 10 9 /l was 30 days in the UCB group and 17 days in the MM URD group (Table 2, Figure 1 ). Time to plt engraftment of 430 Â 10 9 and 450 Â 10 9 /l was also delayed in the UCB group ( Table 2 ). The median number of erythrocyte units was 3 in the UCB group vs 10 in the MM URD group (P ¼ 0.001; Table 2 ). Because of widespread infection and severe mucositis, five patients in the UCB group and three in the MM URD group were given granulocyte transfusions.
Donor chimerism
At 100 days, CD3 þ DC was achieved in 15 of 24 UCB patients (63%) and 4 of 9 MM URD patients (44%). At 1 year, DC was above 80% in the UCB group but unchanged in the MM URD group (Figure 2) . After 100 days of HSCT, CD19 þ DC was 71% (17/24) in the UCB patients and 44% (4/9) in the MM URD patients. The corresponding Acute and chronic GVHD Of the UCB patients, 14 did not have any acute GVHD, as opposed to 7 in the MM URD group. The cumulative incidence of acute GVHD of grades II-IV was 30% in the UCB group and 21% in the MM URD group. Two patients in each group developed chronic GVHD with a cumulative incidence of 9% in the UCB group and 20% in the MM URD group.
Infections
Bacteremia during the pancytopenic phase occurred in 19 patients in the UCB group (70%), and 11 in the MM URD group (79%). The incidence of herpes simplex virus infection was similar in the two groups, 22% in the UCB patients and 29% in the MM URD patients. CMV infection was seen in 13 and 7 patients, respectively (52 and 50%). CMV disease was diagnosed in three of the UCB patients (11%), but in none of the recipients of mismatched grafts. EBV post-transplant lymphoproliferative disorder (EBV-PTLD) was seen in two patients in each of the two groups.
Survival and causes of death TRM was 30% in the UCB patients and 50% in the MM URD group. In the recipients with malignancies, the incidence of relapse at 3 years was 26% among the UCB patients (n ¼ 18) and 40% among the MM URD patients (n ¼ 10). In patients with malignancies, relapse-free survival at 3 years was 43 and 10%, respectively, in the two groups. After considering all patients, overall survival at 3 years was 66% in the UCB group, as compared with 14% in the MM URD group (P ¼ 0.006; Figure 3) . Recipients of single UCB (n ¼ 18) had a survival plateau of 76%, as compared with 46% in those who received double UCB transplants (n ¼ 9).
Causes of death were relapse one in the UCB group and four in the MM URD group. Infectious death occurred in five and four patients, respectively, in these two groups. Two patients in the MM URD group died from acute GVHD. Other causes of death were recorded in two patients in each of the two groups, respectively.
Discussion
In patients with rare HLA alleles, there may be different treatment strategies for selection of the optimal donor. During the 1980s, we used related HLA-mismatched donors with encouraging results combining CYA with MTX vs monotherapy. 28 With an increasing volunteer donor pool during the 1990s, we used more unrelated donors, most being well matched and with results similar to those using HLA-identical sibling donors. 5, 20 In patients without a matched donor, we selected a donor who was mismatched for one HLA-A, -B or -DRb1 Ag, because this can be found for almost all patients. The results were discouraging, and therefore we sought an alternative approach. In contrast to a donor search, which can take a month or more, UCB has the advantage of being ready available. 8, 10, 11 In comparative studies, UCB has shown overall survival similar to that of matched URD transplants. [8] [9] [10] [11] Both UCB patients and MM URD patients have an increased risk of graft failure. 1, 8, 10, 11 Furthermore, T-cell depletion, which was used in the MM URD group, increases the risk of graft failure. 29 In all patients taken together, the overall incidence of graft failure was 12%, with a similar risk in the two cohorts of patients. As expected, engraftment of neutrophils and plts was delayed using UCB, which is in accordance with previous experience. 8, 9, 11 The time to reach an ANC of 40.5 Â 10 9 /l was 30 days in the UCB patients, which is comparable to the results of reports from other groups. 8, 10, 13 Despite the delayed time of plt engraftment, the requirements for plt transfusions were the same using UCB or MM URD ( Table 2) .
The probability of moderate-to-severe acute GVHD was low in both groups. UCB from a related or an unrelated donor has a low incidence of acute GVHD. This is due to low alloreactivity and immune tolerance of these cells, 8, 10, 11 this permit transplantation despite one or two major HLAAg mismatches. The low risk of acute GVHD of grades II-IV in the MM URD patients is due to T-cell depletion. The probability of chronic GVHD was low in both groups. In the UCB group, this is in keeping with reports from other workers. 8, 10, 11, 13 There is also a correlation between acute and chronic GVHD; thus, a low incidence of chronic GVHD was expected in both groups.
The risk of bacteremia was high in both groups (70 and 79%), which might be expected. UCB patients had a longterm neutropenia and all patients were treated with ATG, which persists in serum several weeks after transplantation. 30 ATG affects not only T cells but also other cell populations, such as granulocytes, which are important in fighting bacteria.
EBV-PTLD is a relatively rare complication after ASCT. However, under some circumstances such as HLA and EBV mismatches between recipient and donor, there is an increased risk of EBV-PTLD. 31 In patients with no risk criteria, the risk of EBV-PTLD is less than 1%. In this study, the overall probability of EBV-PTLD was 10%, and is similar in the two study groups. Of the recipients of T-cell-depleted MM URD, four patients with an increase in EBV load were treated with adoptive donor EBV-specific cytotoxic T lymphocytes to prevent EBV-PTLD. 32 Brunstein et al. 33 found that EBV-PTLD in recipients of UCB was linked to the use of ATG. ATG may have contributed to EBV-PTLD in our patients.
There are limited data on chimerism analysis after UCB. In some reports, complete DC has been reported in 50-94% of surviving patients with engraftment. 9, 34, 35 We found that for CD3 þ , CD19 þ and CD33 þ , complete DC was similar in the two study groups at day 100: B60 to 70% and increasing slightly with time. Using reduced-intensity conditioning, Barker et al. 7 reported complete DC in 76-94% of UCB recipients, depending on the conditioning regimen.
TRM was 30% in the UCB patients at 3 years. This compares favorably with the 100-day TRM reported for UCB by other groups, being between 20 and 55%. [8] [9] [10] [11] Using reduced-intensity conditioning and UCB, TRM was reported to be similar to or lower than our experience. [33] [34] [35] On account of the small number of patients and the heterogeneity in our study, caution must be exercised with regard to some of the findings. Even so, survival was encouraging in the UCB group with a 3-year survival of 66%. This is similar to the best reports using UCB. 8, 10, 34 It is also comparable to the results of a recent report from the Center for International Blood and Marrow Transplant Research in patients receiving HLA-identical UCB. 36 In that study, children with acute leukemia who received HLA-identical UCB showed better survival than those receiving HLA-mismatched UCB and also recipients of BM from HLA-A, -B -C and DRb1 identical donors, where leukemia-free survival was around 40%. As expected, the MM URD patients did poorly compare to the outcome in the recipients of MUD transplants. 20 This study includes a small number of patients including varying underlying diseases and different transplantation procedures. The patients were also transplanted during two different time periods. Therefore, improvement with time may have had an impact on outcome. As seen in similar patients undergoing transplants with matched URD during these two different time periods, there was a slight but nonsignificant improvement in survival with time (P ¼ 0.3 for patients with high-risk leukemia). Therefore, cell source is probably the main reason for the improved survival. Thus, our future strategy for patients who do not have an HLA-identical donor is to select an UCB with mismatch in no more than two major HLA Ags.
In conclusion, UCB is a promising alternative to MM URD transplantation.
